187 related articles for article (PubMed ID: 15190520)
1. Transplant strategies for idiopathic myelofibrosis.
McCarty JM
Semin Hematol; 2004 Apr; 41(2 Suppl 3):23-9. PubMed ID: 15190520
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
4. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
5. Biology and management of idiopathic myelofibrosis.
Smith BD; Moliterno AR
Curr Opin Oncol; 2001 Mar; 13(2):91-4. PubMed ID: 11224705
[TBL] [Abstract][Full Text] [Related]
6. Transplant decision-making strategies in the myeloproliferative disorders.
Fruchtman SM
Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic Stem Cell Transplantation in Myelofibrosis.
Jain T; Mesa RA; Palmer JM
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1429-1436. PubMed ID: 28499938
[TBL] [Abstract][Full Text] [Related]
8. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
Michiels JJ; Thiele J
Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
[TBL] [Abstract][Full Text] [Related]
10. Idiopathic myelofibrosis without dacryocytes.
Chen GL; Liu E; Naidoo K; Popat U; Coetzer TL; Prchal JT
Haematologica; 2006 Jun; 91(6 Suppl):ECR29. PubMed ID: 16785132
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
Alchalby H; Kröger N
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
[TBL] [Abstract][Full Text] [Related]
12. The forgotten myeloproliferative disorder: myeloid metaplasia.
Tefferi A
Oncologist; 2003; 8(3):225-31. PubMed ID: 12773744
[TBL] [Abstract][Full Text] [Related]
13. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
[TBL] [Abstract][Full Text] [Related]
14. [Chronic myeloproliferative disorders. The new WHO classification].
Thiele J; Kvasnicka HM
Pathologe; 2001 Nov; 22(6):429-43. PubMed ID: 11766643
[TBL] [Abstract][Full Text] [Related]
15. Idiopathic myelofibrosis.
Barosi G; Hoffman R
Semin Hematol; 2005 Oct; 42(4):248-58. PubMed ID: 16210038
[TBL] [Abstract][Full Text] [Related]
16. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment.
Hoffman R; Prchal JT; Samuelson S; Ciurea SO; Rondelli D
Biol Blood Marrow Transplant; 2007 Jan; 13(1 Suppl 1):64-72. PubMed ID: 17222772
[TBL] [Abstract][Full Text] [Related]
17. [Myeloproliferative disorders].
Binder D; Fehr J
Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloproliferative disorders.
Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
[TBL] [Abstract][Full Text] [Related]
19. CD34+ stem cells in chronic myeloproliferative disorders.
Thiele J; Kvasnicka HM
Histol Histopathol; 2002 Apr; 17(2):507-21. PubMed ID: 11962756
[TBL] [Abstract][Full Text] [Related]
20. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
